TWST - Twist Bioscience: NGS Is Taking Off
2024-05-03 13:32:54 ET
Summary
- Market conditions remain tough for biotech companies, but Twist continues to perform well compared to peers.
- Twist Bioscience's second quarter results were strong, driven by NGS demand, and the company expects this strength to continue.
- Twist's valuation probably limits near-term upside, but the company continues to look attractive for long-term investors.
- Cash burn will remain front of mind for investors, but Twist is on track to achieve breakeven without requiring additional capital.
Twist Bioscience's ( TWST ) second quarter results were strong on the back of NGS demand, and based on guidance, this strength is likely to continue. While Twist's losses remain large, the company still has a sizeable cash balance, and cash burn should moderate in coming quarters....
Twist Bioscience: NGS Is Taking Off